


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313 on June 27, 2006.

INFORMATION DISCLOSURE  
STATEMENT  
Patent Application  
Docket No. SER-104  
Serial No. 10/553,135

  
Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Giampiero de Luca  
Serial No. : 10/553,135  
Filed : October 14, 2005  
Conf. No. : 1670  
For : Interferon Beta in Severe Acute Respiratory Syndrome (SARS)

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, Applicant has not submitted copies of the published U.S. Patent Applications cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/gyl

Attachments: Form PTO/SB/08; copies of cited references  
Copy of International Search Report.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/553,135
				Filing Date	October 14, 2005
				First Named Inventor	Giampiero de Luca
				Art Unit	not yet assigned
				Examiner Name	not yet assigned
Sheet	1	of	3	Attorney Docket Number	SER-104

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2005/0137154	06-23-2005	Carter <i>et al.</i>	All
	U2	US-2006/0035859	02-16-2006	Carter <i>et al.</i>	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	F1	WO 2005/009337	02-03-2005	HEMISPHERx BIOPHARMA	All	
	F2	WO 2004/100980	11-25-2004	VIRAGEN, INC.	All	
	F3	WO 03/031587	04-17-2003	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	All	
	F4	EPO 1 213 029	06-12-2002	SCHERING CORPORATION	All	
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/553,135	
			Filing Date	October 14, 2005	
			First Named Inventor	Giampiero de Luca	
			Group Art Unit	not yet assigned	
			Examiner Name	not yet assigned	
Sheet	2	of	3	Attorney Docket Number	SER-104

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	CINATL, J. <i>et al.</i> "Treatment of SARS with human interferons", <i>The Lancet</i> , July 26, 2003, pp. 293-294, Vol. 362.	
	R2	CLEGG, A. <i>et al.</i> "Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness", <i>Exp. Opin. Pharmacother.</i> , 2001, pp. 623-639, Vol. 2, No. 4.	
	R3	DERYNCK, R. <i>et al.</i> "Isolation and structure of a human fibroblast interferon gene", <i>Nature</i> , June 19, 1980, pp. 542-547, Vol. 285.	
	R4	DROSTEN, C. <i>et al.</i> "Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome", <i>The New England Journal of Medicine</i> , April 10, 2003, pp. 1-10, retrieved from <a href="http://www.nejm.org">www.nejm.org</a> .	
	R5	FAMILLETTI, P.C. <i>et al.</i> "A Convenient and Rapid Cytopathic Effect Inhibition Assay for Interferon", <i>Methods in Enzymology</i> , pp. 387-394, Vol. 78.	
	R6	KSIAZEK, T.G. <i>et al.</i> "A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome", <i>The New England Journal of Medicine</i> , April 10, 2003, pp. 1-12, retrieved from <a href="http://www.nejm.org">www.nejm.org</a> .	
	R7	MARK, D.F. <i>et al.</i> "Site-specific mutagenesis of the human fibroblast interferon gene", <i>Proc. Natl. Acad. Sci. USA</i> , September 1984, pp. 5662-5666, Vol. 81.	
	R8	MCCORMICK, J.B. <i>et al.</i> "Lassa Fever- Effective Therapy with Ribavirin", <i>The New England Journal of Medicine</i> , January 2, 1986, pp. 20-26, Vol. 314.	
	R9	PESTKA, S. <i>et al.</i> "Interferon Standards and General Abbreviations", <i>Methods in Enzymology</i> , 1986, pp. 14-23, Vol. 119.	
	R10	RUBINSTEIN, S. <i>et al.</i> "Convenient Assay for Interferons", <i>Journal of Virology</i> , February 1981, pp. 755-758, Vol. 37, No. 2.	
	R11	SHEPARD, H.M. <i>et al.</i> "A single amino acid change in INF- $\beta_1$ abolishes its antiviral activity", <i>Nature</i> , December 10, 1981, pp. 563-565, Vol. 294.	
	R12	TOGO, Y. <i>et al.</i> "Chemoprophylaxis and Therapy of Respiratory Viral Infections: Double-Blind Clinical Assessment of Ribarvirin (Virazole) in the Prevention of Induced Infection with Type B Influenza Virus", <i>The Journal of Infectious Diseases</i> , June 1976, pp. A109-A113, Vol. 133, Supplement.	
	R13	STUDY GROUP, "Randomised double-blind placebo-controlled study of interferon $\beta$ -1a in relapsing/remitting multiple sclerosis", <i>The Lancet</i> , November 7, 1998, pp. 1498-1504, Vol. 352.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/553,135	
			Filing Date	October 14, 2005	
			First Named Inventor	Giampiero de Luca	
			Group Art Unit	not yet assigned	
			Examiner Name	not yet assigned	
			Attorney Docket Number	SER-104	
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R14	HIGGINS, P.G. <i>et al.</i> "Intranasal Interferon as Protection Against Experimental Respiratory Coronavirus Infection in Volunteers", <i>Antimicrobial Agents and Chemotherapy</i> , November 1983, pp. 713-715, Vol. 24, No. 5.	
	R15	Database SCISEARCH 'Online!', Accession No. 2002:896651; TRUYEN, U. <i>et al.</i> "Antiviral Potency of interferon-omega (IFN-omega) against selected canine and feline viruses", <i>Praktische Tierarzt</i> , October 1, 2002, pg. 862, Vol. 83, No. 10., XP002252700.	
	R16	Database BIOSIS 'Online!', Accession No. PREV200100181684; HABERSETZER, F. <i>et al.</i> "A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C", <i>Liver</i> , December 2000, Abstract only, Vol. 20, No. 6., XP002252701.	
	R17	Database SCISEARCH 'Online!', "Treatment of SARS with human interferons", <i>Lancet</i> , July 26, 2003, Vol. 362, No. 9380, XP002252699.	
	R18	Database WPI, Section Ch, Week 200315, Derwent Publications LTD., London, GB; Class B04, AN 2003-150867, Abstract only, XP002252702.	
	R19	HULTGREN, C. <i>et al.</i> "The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses", <i>Journal of General Virology</i> , 1998, pp. 2381-2391, Vol. 79.	
	R20	TAM, R.C. <i>et al.</i> "Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile", <i>Journal of Hepatology</i> , 1999, pp. 376-382, Vol. 30.	
	R21		
	R22		
	R23		
	R24		
	R25		
	R26		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.